MiRNA-574-3p inhibits cell progression by directly targeting CCND2 in colorectal cancer
Authors: Yan-Qiong Wu
Juan-Juan Zhang
Bo Gao
Wen-Cui Li
Chao-Yun Wang
Journal: Bioscience Reports (2019)
Discipline: MOLECULAR BIOLOGY & GENETICS
Keywords: Cyclin D2 (CCND2); apoptosis; colorectal cancer (CRC); microRNA-574-3p; migration
Affiliations: Department of Laboratory Medicine, Taihe Hospital, Hubei University of Medicine, Shiyan 442000, Hubei Province, China, Department of Anesthesiology, Taihe Hospital, Hubei University of Medicine, Shiyan 442000, Hubei Province, China, Reproductive Medicine Center, Taihe Hospital, Hubei University of Medicine, Shiyan 442000, Hubei Province, China

Abstract:  Colorectal cancer (CRC) remains the candidate for one of the typical types of malignant tumors of in gastrointestinal tract all around the world, which leads to tremendous death and ranks as the top leading death of cancer. Recently, microRNAs have emerged as double-edged sword in numerous cancers. This investigation aims to discuss the regulative role of microRNA-574-3p (miR-574-3p), elucidating its molecular mechanism and clinical significance in CRC. Herein, it revealed to us that miR-574-3p was lowly expressed in CRC tissues in comparison with the matched paracarcinoma tissues. In addition, transfection of SW480 and HT29 cells with miR-574-3p mimics prohibited the post-transcriptional expression of Cyclin D2 (CCND2), which then significantly blocked cell growth and cell migration, yet triggered cell apoptosis. Also, dual-luciferase reporter assays proved the role of CCND2 as the targeted gene for miR-574-3p. miR-574-3p overexpression prohibited the activity of CCND2 in SW480 and HT29 cells. Silencing of CCND2 in SW480 and HT29 CRC cell lines leading to reduced cell proliferative and migrative rates, and enhanced apoptotic rate. The suppressive effects of elevation of miR-574-3p on the proliferation of the human CRC cells and promotive effects on cell apoptosis by targeting CCND2 were further illustrated in the in vitro studies. Thus, we hypothesize that miR-574-3p may be served as a prospective therapeutic candidate for CRC. 

Retracted: No

PubPeer comments:
 The images in Figure 3A and 3B appear to have some concerning repeated elements. Using the NC image of the invasion of HT29 cells as an example, with repeated elements indicated with like color, immediately below is a clone illustration from Forensically on the same image. Apologies for the crude mark-up. Other panels have similar issues. *** ![file] *** Full figure ![file] , 
 Fig 4A. ![file] Comparing the NC SW480 and HD29 panels, more cells than one would expect appear in the same place, and cancel out from a color-reverse overlay. ![file] Other FACS panels also reward close attention. ![file] , 
 #1 ![] Improved by horizontal flips 180-deg rotations. ![] , 
 https: doi.org 10.1042 BSR-20190976_EOC The Editorial Office has been made aware of potential issues surrounding the scientific validity of this paper, hence has issued an expression of concern to notify readers whilst the Editorial Office investigates. , 
 Unclear why the journal has not yet acted on this paper as they have on others. , 
 Retracted [24 August 2021] . --------------------------- This Retraction follows an Expression of Concern relating to this article previously published by Portland Press. This article is being retracted from Bioscience Reports at the request of the Editor-in-Chief and the Editorial Board following receipt of a notification from a reader, alerting the authors to duplicated sections in Figures 3A, 3B and 4A. The authors have been contacted in regards to the Retraction, and have not responded to the Journal s queries and the concerns raised. Given the extent of the issues raised, the Editorial Board stand by the decision to retract the article. , 
 In the interests of dead-horse flogging, I want to point out some of the source material for figures in this paper. *[left]* here is Fig 3B. *[right]* Fig 6B from  miR-4317 suppresses non-small cell lung cancer (NSCLC) by targeting fibroblast growth factor 9 (FGF9) and cyclin D2 ([He et al 2018] ). ![] Here, two matched panels, re-scaled to make the common features more obvious. ![file] ,